Table 1. Summary of the patient characteristics across all countries.
| LTFU | In care | Deaths | All patients | |||||
|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | n | (%) | |
| Total | 743 | 7210 | 352 | 8305 | (100) | |||
| Year of ART initiation | ||||||||
| 2003-05 | 67 | (9) | 564 | (8) | 75 | (21) | 706 | (9) |
| 2006-09 | 396 | (53) | 2240 | (31) | 124 | (35) | 2760 | (33) |
| 2010-13 | 280 | (38) | 4406 | (61) | 153 | (43) | 4839 | (58) |
| Age | ||||||||
| ≤30 | 245 | (33) | 1986 | (28) | 69 | (20) | 2300 | (28) |
| 31-40 | 255 | (34) | 2950 | (41) | 131 | (37) | 3336 | (40) |
| 41-50 | 150 | (20) | 1399 | (19) | 68 | (19) | 1617 | (19) |
| 51+ | 93 | (13) | 875 | (12) | 84 | (24) | 1052 | (13) |
| Median [IQR] | 35 | [29, 44] | 35 | [30, 43] | 39 | [32, 50] | 35 | [30, 44] |
| Sex | ||||||||
| Male | 503 | (68) | 4929 | (68) | 280 | (80) | 5712 | (69) |
| Female | 240 | (32) | 2276 | (32) | 69 | (20) | 2585 | (31) |
| Transgender | 0 | (-) | 5 | (0) | 3 | (1) | 8 | (<0.2) |
| Mode of HIV exposure | ||||||||
| Heterosexual | 503 | (68) | 4805 | (67) | 213 | (61) | 5521 | (66) |
| Homosexual contact | 106 | (14) | 1113 | (15) | 34 | (10) | 1253 | (15) |
| Injecting drug user | 65 | (9) | 584 | (8) | 66 | (19) | 715 | (9) |
| Other/Unknown | 69 | (9) | 708 | (10) | 39 | (11) | 816 | (10) |
| HCV (ever) | ||||||||
| Negative | 499 | (67) | 5387 | (75) | 237 | (67) | 6123 | (74) |
| Positive | 73 | (10) | 819 | (11) | 68 | (19) | 960 | (12) |
| Not tested | 171 | (23) | 1004 | (14) | 47 | (13) | 1222 | (15) |
| HBV (ever) | ||||||||
| Negative | 519 | (70) | 5634 | (78) | 271 | (77) | 6424 | (77) |
| Positive | 59 | (8) | 634 | (9) | 40 | (11) | 733 | (9) |
| Not tested | 165 | (22) | 942 | (13) | 41 | (12) | 1148 | (14) |
| Pre-ART CD4 (cells/μL) | ||||||||
| ≤50 | 239 | (32) | 2104 | (29) | 174 | (49) | 2517 | (30) |
| 51-100 | 100 | (13) | 839 | (12) | 74 | (21) | 1013 | (12) |
| 101-200 | 154 | (21) | 1295 | (18) | 48 | (14) | 1497 | (18) |
| >200 | 194 | (26) | 2316 | (32) | 29 | (8) | 2539 | (31) |
| Not tested | 56 | (8) | 656 | (9) | 27 | (8) | 739 | (9) |
| Median [IQR] | 108 | [30, 217] | 126 | [34, 246] | 45 | [16, 97] | 117 | [32, 239] |
| Pre-ART viral load (copies/mL) | ||||||||
| ≤10ˆ5 | 75 | (10) | 1138 | (16) | 42 | (12) | 1255 | (15) |
| >10ˆ5 | 56 | (8) | 1177 | (16) | 67 | (19) | 1300 | (16) |
| Not tested | 612 | (82) | 4895 | (68) | 243 | (69) | 5750 | (69) |
| Median [IQR] | 62000 | [20303,264000] | 105 000 | [30 500,362 400] | 151 900 | [70 500,380 840] | 105000 | [30589,358000] |
| First ART regimen | ||||||||
| NRTI+NNRTI | 700 | (94) | 6618 | (92) | 313 | (89) | 7631 | (92) |
| NRTI+PI | 41 | (6) | 505 | (7) | 37 | (11) | 583 | (7) |
| Other | 2 | (0) | 87 | (1) | 2 | (1) | 91 | (1) |
| Previous mono/dual therapy | ||||||||
| No | 728 | (98) | 7061 | (98) | 329 | (93) | 8118 | (98) |
| Yes | 15 | (2) | 149 | (2) | 23 | (7) | 187 | (2) |
| Clinical Site | ||||||||
| Cambodia | 323 | (44) | 2115 | (29) | 97 | (28) | 2535 | (30) |
| Hong Kong | 14 | (2) | 704 | (10) | 76 | (22) | 794 | (10) |
| Indonesia | 114 | (15) | 954 | (13) | 29 | (8) | 1097 | (13) |
| Singapore | 222 | (30) | 1529 | (21) | 50 | (14) | 1801 | (22) |
| Vietnam | 33 | (4) | 1467 | (21) | 92 | (26) | 1592 | (19) |
| South Korea | 37 | (5) | 441 | (6) | 8 | (2) | 486 | (6) |